Navigation Links
Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Date:1/28/2010

Social Network Analysis of 11 disease areas shows that current KOL identification methods produce inaccurate results; relationship models are more effective than bibliometric lists in measuring KOL impact

(PRWEB) January 28, 2010 -- A new white paper challenges the generally-held notion that scientists who are “productive” in terms of publishing are well connected and meaningful to the community. Research firm Lnx Pharma found that in a large number of cases, the opposite was true.

This study questions the current methodology used extensively in pharmaceutical and biotech industries to find Key Opinion Leaders (KOLs) and influential thought leaders. KOLs are a key part of pharmaceutical marketing, discovery and development stages.

“Companies typically use a combination of personal referrals plus standard bibliometrics to find and evaluate candidates for advocacy and advisory roles in drug development,” said Philip Topham, General Manager of Lnx Pharma. “They consider it to be more of an art form than science - qualitative information is layered with publishing counts and speaking engagements data in order to judge the potential value of KOLs. We can now quantify that this methodology is leaving a large number of truly respected thought leaders out of the consideration set.”

Lnx Pharma research shows that bibliometrics as a means of discovering and ranking potential product advocates fails to find over 50% of the truly respected experts, compared to using the more advanced Large Scale Social Network Analysis (SNA). Lnx Pharma is a research company that uses SNA to help pharmaceutical companies to map thought leadership and marketing strategies.

The LS-SNA method was used to evaluate more than 20 different disease state areas including:
        

 
  • Obesity
  •         
  • Blood Coagulation Disorders
  •         
  • Infectious Diseases
  •         
  • Autism
  •         
  • Cardiology
  •         
  • Oncology - Breast
  •         
  • Oncology - Lung
  •         
  • Oncology - Ovarian
  •         
  • Oncology - Colorectal
  •         
  • Rheumatology
  •         
  • Central Nervous System
  •         
  • Diagnostics & Biomarkers
  •         
  • Insomnia
  •         
  • Diabetes
The complex relationships between researchers contain a wealth of information that can be extracted using Large Scale Social Network Analysis. Consequently it is only natural to use research publications to identify experts or key opinion leaders (KOLs.) Yet for all the wealth of information, no amount of counting publications will determine “respect.” A person could publish 10 times or 100 times and still not be respected. And yet, companies continue to utilize this outdated an ineffective technique.

The full white paper may be downloaded from the Lnx Pharma website: http://bit.ly/whitepaper6

About Lnx Pharma
Lnx Pharma is a division of Lnx Research, LLC a privately held company based in Irvine, California, dedicated to leadership in the analysis of knowledge-creating communities. Lnx Research utilizes proprietary social network analysis methods and technologies to identify and understand "The Invisible College" of key opinion leaders in order to answer questions about knowledge communities for government and commercial clients in multiple industries. For white papers on this topic, or more specific information on Lnx Pharma, email info(at)lnxpharma(dot)com, or see http://www.lnxpharma.com.

# # #

Read the full story at http://www.prweb.com/releases/pharmaceutical-marketing/kol-management/prweb3538204.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Standard Management Announces OTCBB Listing
3. Gastroenterology sets standards for CT colonography
4. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
5. New Drug No Substitute for Standard Blood-Clot Therapy
6. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
7. New guidelines set to improve standard of cows milk allergy care
8. Green Seal Ramps Up Environmental Standard for Household Cleaners
9. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
10. Standard treatment for prostate cancer may encourage spread of disease
11. Health Literacy Innovations Releases New Survey on Medicaid Health Literacy Standards
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders 
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has ... camp held at Oregon State University this summer. Employing world-class rugby figures, including former ... all skill levels with training on key fundamentals, match play, fitness and more. , ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery Channel. ... vision of becoming a leader in optimized drug discovery through innovative cellular analysis. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of ... for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: ... Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, and ...
(Date:5/6/2016)... ... ... Canadian author Mark Black is a speaker, author, and life strategy coach who ... … with the help of his publisher Strategic Book Group and its subsidiary Publish ... bed waiting for a miracle: He needed a heart and double-lung transplant. From this came ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
Breaking Medicine Technology: